Steroid Ointment Beats Tacrolimus at Clearing Early Skin Lymphoma, but Relapses Loom

A rare cancer of the immune system that hides in plain sight on the skin may soon be treated with sharper logic, thanks to a head-to-head comparison of two everyday ointments. Mycosis fungoides, the most common form of cutaneous T-cell lymphoma, begins insidiously as scaly patches and plaques that mimic eczema or psoriasis, and for most patients whose disease is caught at an early stage, the first line of defense is not chemotherapy but medicine rubbed directly onto the affected skin. A new retrospective study from dermatologists at Şişli Hamidiye Etfal Training and Research Hospital in Istanbul, published in the Archives of Dermatological Research, has now pitted a super-potent topical corticosteroid against a steroid-free immune modulator in forty patients with stage IA or IB disease, and the results sketch a genuinely nuanced picture of how these two very different drugs perform.

The trial compared 0.05 percent clobetasol propionate ointment, one of the strongest topical steroids in clinical use, with 0.1 percent tacrolimus ointment, a calcineurin inhibitor best known for treating atopic dermatitis. Twenty patients received each treatment. The question matters because early-stage mycosis fungoides is highly treatable with skin-directed therapies, yet the ideal first-choice agent has remained contested. Topical steroids are cheap, familiar, and fast, but long-term use carries the familiar toll of skin atrophy, striae, telangiectasia, and taper-dependent relapse. Tacrolimus offers a steroid-sparing alternative that suppresses T-cell activation without thinning the skin, but direct comparative evidence against clobetasol in lymphoma patients has been almost nonexistent until now.

On raw clearance rates, the verdict was lopsided. In the clobetasol group, 95 percent of patients achieved a complete clinical response, meaning their lesions resolved entirely, and the remaining 5 percent achieved a partial response. In the tacrolimus group, by contrast, only 60 percent reached complete clearance and 20 percent a partial response. The median time to complete response also favored the steroid, at two months versus three and a half months for tacrolimus, although that timing difference did not reach statistical significance. For clinicians and patients alike, the message of the first analysis is straightforward: clobetasol clears early patches and plaques faster and more often.

But the story changed when the researchers followed patients forward in time. Among those who achieved complete clearance, relapse occurred in 63.2 percent of the clobetasol-treated patients compared with just 25 percent of those treated with tacrolimus, a difference that approached but did not reach conventional statistical significance. Kaplan-Meier survival analysis, which tracks how long patients remain disease-free over months and years, showed a trend toward longer relapse-free survival in the tacrolimus group, with a log-rank p-value of 0.060. In a study of only forty patients, trends of this size are tantalizing rather than definitive, but they hint at a trade-off that clinicians have long suspected: steroids win the sprint while tacrolimus may hold ground longer in the marathon.

The biology behind that trade-off is worth unpacking. Mycosis fungoides is driven by clonal malignant T lymphocytes that home to the skin, and both drugs attack the inflammatory machinery these cells depend on, but by different routes. Clobetasol binds intracellular glucocorticoid receptors, broadly repressing transcription of inflammatory cytokines and inducing apoptosis in immune cells, a blunt but powerful instrument. Tacrolimus inhibits calcineurin, a phosphatase essential for activating the transcription factor NFAT in T cells, thereby blocking interleukin-2 production and T-cell proliferation with far greater selectivity. Because the steroid suppresses inflammation indiscriminately, it clears lesions dramatically, but once therapy stops or is tapered, the underlying malignant clone may rebound quickly. Calcineurin inhibition, gentler and more targeted, may leave residual disease control in place even as visible lesions fade more slowly.

Safety considerations sharpen the clinical calculus further. Prolonged use of super-potent steroids on thin skin, on the face, or in folds produces atrophy, striae, and secondary infection, and mycosis fungoides frequently affects these vulnerable sites and demands years of intermittent treatment. Tacrolimus ointment does not cause skin thinning, which is precisely why dermatologists have proposed it as a steroid-sparing option, and earlier work including a phase 2 trial of the related calcineurin inhibitor pimecrolimus published in The Lancet Haematology in 2022 demonstrated meaningful activity and tolerability in early-stage disease. One historical concern, a theoretical lymphoma risk from systemic absorption of calcineurin inhibitors, has been substantially allayed by large cohort studies such as the JOELLE investigations, which followed tens of thousands of users and found no convincing increase in lymphoma incidence, and pharmacokinetic studies showing minimal systemic exposure when tacrolimus is applied to intact skin.

The Istanbul team’s findings also sit within a growing evidence base for topical therapy in this lymphoma. Zackheim’s foundational work established patch-stage mycosis fungoides as responsive to potent topical corticosteroids, and a 2025 comparison from the same Turkish group, published in the Brazilian Annals of Dermatology, found clobetasol competitive with oral bexarotene in early disease. What has been missing is exactly the kind of direct steroid-versus-calcineurin-inhibitor comparison this study provides, even in retrospective form. The authors themselves caution that comparative data on topical therapies remain limited and that calcineurin inhibitors have been proposed as steroid-sparing alternatives largely on theoretical and indirect grounds.

The study’s limitations deserve honest weight. Forty patients divided into two groups of twenty, treated retrospectively rather than randomized, leave ample room for selection bias, confounding by disease severity or anatomical site, and underpowered statistics. Relapse definitions and follow-up duration are critical in a disease whose natural history is measured in decades, and differences that miss significance at p-values just above 0.05, as several here do, could easily prove real in a larger cohort or dissolve into noise. The authors do not claim that tacrolimus prevents relapse; they report trends. Still, in rare diseases, randomized trials are notoriously difficult to populate, and carefully collected comparative cohort data like this often guides practice for years before definitive evidence arrives.

For patients, the practical takeaway is a conversation rather than a prescription. Someone with extensive thin plaques on the face or flexures, or a history of steroid-induced skin damage, may reasonably begin with tacrolimus, accepting slower clearance and a somewhat lower chance of complete response in exchange for durability and skin preservation. Someone with thicker, widespread plaques and a need for rapid control may start with clobetasol, then consider rotating to or maintaining with a calcineurin inhibitor to hold the gains while sparing the skin. The pattern in this data, fast clearance with higher relapse on one side and slower, stickier remission on the other, maps neatly onto that sequential strategy, which many dermatologists already employ empirically.

What happens next is the familiar rhythm of clinical oncology: these findings need prospective confirmation, ideally in a randomized trial with standardized response criteria under the current ISCL-EORTC staging framework, longer follow-up to truly characterize relapse-free survival, and enough patients to convert suggestive p-values into conclusions. Until then, the Istanbul study earns its place as one of the few direct comparisons of the two most accessible topical treatments for early mycosis fungoides, and it reframes the question clinicians ask at the bedside. It is no longer simply which ointment clears the skin, but which ointment keeps it clear, and the answer may be that the humble immunomodulator cream, long relegated to second-line status, deserves a more prominent seat at the table for carefully selected patients facing this indolent lymphoma.

Subject of Research: Comparative efficacy of topical corticosteroid versus calcineurin inhibitor therapy in early-stage mycosis fungoides

Article Title: Comparison of the efficacy of topical 0.05% clobetasol propionate and topical 0.1% tacrolimus in the treatment of early-stage mycosis fungoides

Article References: Comparison of the efficacy of topical 0.05% clobetasol propionate and topical 0.1% tacrolimus in the treatment of early-stage mycosis fungoides. (n.d.). https://doi.org/10.1007/s00403-026-04958-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04958-0

Keywords: mycosis fungoides, cutaneous T-cell lymphoma, clobetasol propionate, tacrolimus, topical therapy, dermatology, relapse-free survival, calcineurin inhibitors, skin-directed treatment, clinical research, Comparison, efficacy